Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Approval Alert: Petrovax Pharm’s Biosimilar Denosumab First to Receive Russian Approval

Apr 15, 2025

On 15 April 2025, Petrovax Pharm announced that it is launching its denosumab biosimilar (Forsedeno®) in the Russian market after the Russian Ministry of Health granted marketing authorisation.  This marks Russia’s first approved denosumab biosimilar to Amgen’s Prolia/Xgeva.

Petrovax Pharm acquired the rights to the denosumab biosimilar in Russia under an agreement with AryoGen Pharmed (part of CinnaGen Group).

In August 2024 Bio-Thera and Pharmapark entered a licence and supply agreement for a secukinumab biosimilar in Russia.